GlaxoSmithKline Pharmaceuticals Shares Experience Volume Surge, Rise by 7.90%
With a neutral sentiment as of May 8, 2025, according to Moneycontrol analysis, GlaxoSmithKline Pharmaceuticals demonstrates significant volume and price movement, driven by consistent financial performance.
Alpha Desk
May 14, 2025 / 10:34 IST
DisclaimerThis is an AI-assisted live blog with updates sourced from multiple news outlets and agenciesDisclaimer
GlaxoSmithKline Pharmaceuticals experienced a notable surge in trading volume during today's session, with shares climbing 7.90% to reach Rs 3008.90. The significant increase in volume suggests heightened investor interest in the stock.
The stock is part of the NIFTY MIDCAP 150 index. The increased activity may reflect renewed confidence or strategic positioning by investors.
Here’s a snapshot of the company's consolidated quarterly results:
March 2025: Revenue stood at Rs 974.37 Cr, an increase from Rs 949.42 Cr in December 2024.
Net Profit: The company reported a net profit of Rs 262.87 Cr for March 2025, up from Rs 229.88 Cr in the previous quarter.
EPS: Earnings Per Share (EPS) was Rs 15.52 in March, compared to Rs 13.57 in December.
The figures demonstrate a positive trend in the company's financial health.
Annual Performance
A look at the consolidated annual results over the past five years reveals sustained growth:
Revenue: Increased from Rs 2,925.60 Cr in 2021 to Rs 3,749.21 Cr in 2025.
Net Profit: Rose from Rs 287.27 Cr in 2021 to Rs 927.58 Cr in 2025.
EPS: Improved from Rs 31.35 in 2021 to Rs 54.52 in 2025.
BVPS: Book Value Per Share increased from Rs 87.26 in 2021 to Rs 115.18 in 2025.
ROE: Return on Equity grew from 24.22% in 2021 to 47.53% in 2025.
Debt to Equity: The company maintained a debt-to-equity ratio of 0.00 throughout the period.
The consistent financial growth may contribute to positive investor sentiment.
Key Financial Metrics
The following table presents a summary of GlaxoSmithKline Pharmaceuticals' financial performance, with all values in Rs. Cr unless otherwise specified.
Financial Year
Revenue
Net Profit
EPS (Rs.)
BVPS (Rs.)
ROE (%)
Debt to Equity
Mar 2021
2,925.60
287.27
31.35
87.26
24.22
0.00
Mar 2022
3,278.03
380.77
99.29
157.19
63.64
0.00
Mar 2023
3,251.72
607.64
36.08
102.79
35.41
0.00
Mar 2024
3,453.71
589.96
41.14
104.93
33.42
0.00
Mar 2025
3,749.21
927.58
54.52
115.18
47.53
0.00
The table highlights the company's consistent growth in key financial metrics over the past five years. With a neutral sentiment as of May 8, 2025, according to Moneycontrol analysis, GlaxoSmithKline Pharmaceuticals demonstrates significant volume and price movement, driven by consistent financial performance.
